Lupin has launched its Morphine Sulfate ER Tablets 15 mg, 30 mg, 60 mg, 100 mg and 200 mg having received an approval from the United States Food and Drug Administration (USFDA) earlier to market a generic version of Purdue Pharma’s MS Contin ER Tablets 15 mg, 30 mg, 60 mg, 100 mg and 200 mg. MS Contin ER Tablets had US sales of $282.9 million, as per IMS MAT September 2016.
Lupin’s Morphine Sulfate ER Tablets 15 mg, 30 mg, 60 mg, 100 mg and 200 mg are the AB rated generic equivalent of Purdue Pharma’s MS Contin ER Tablets 15 mg, 30 mg, 60 mg, 100 mg and 200 mg. Morphine Sulfate ER Tablets are indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals.
